Kimberly-Clark Company KMB reported fourth-quarter 2020 outcomes, whereby each prime and backside strains beat the Zacks Consensus Estimate and the previous elevated 12 months over 12 months. Energy within the Shopper Tissue and Private Care segments together with financial savings from restructuring plans www.nasdaq.com
Kimberly-Clark Company KMB reported fourth-quarter 2020 outcomes, whereby each prime and backside strains beat the Zacks Consensus Estimate and the previous elevated 12 months over 12 months. Energy within the Shopper Tissue and Private Care segments together with financial savings from restructuring plans
www.nasdaq.com